Andrea Endimiani Gioconda Brigante Alessia A Bettaccini Francesco Luzzaro Paolo Grossi Antonio Q Toniolo
10.1186/1471-2334-5-106
BMC Infect Dis
2005 Nov 24;5:106.
CC BY
https://pubmed.ncbi.nlm.nih.gov/16307682/
Community-Acquired Infections / drug therapy Drug Resistance, Multiple, Bacterial Levofloxacin Ofloxacin / pharmacology Ofloxacin / therapeutic use Pneumonia, Pneumococcal / drug therapy
Community-Acquired Infections / drug therapy Drug Resistance, Multiple, Bacterial Levofloxacin Ofloxacin / pharmacology Ofloxacin / therapeutic use Pneumonia, Pneumococcal / drug therapy Case Reports Research Support, Non-U.S. Gov't Aged Anti-Bacterial Agents Bacterial Proteins / genetics DNA Topoisomerases, Type II / genetics Humans Penicillanic Acid / analogs & derivatives Penicillanic Acid / therapeutic use Piperacillin / therapeutic use Piperacillin, Tazobactam Drug Combination Streptococcus pneumoniae / drug effects Streptococcus pneumoniae / enzymology Streptococcus pneumoniae / genetics Streptolysins / genetics Treatment Failure Anti-Bacterial Agents Bacterial Proteins Streptolysins plY protein, Streptococcus pneumoniae Piperacillin, Tazobactam Drug Combination Levofloxacin Penicillanic Acid Ofloxacin DNA Topoisomerases, Type II Piperacillin
PMC1308815
16307682
Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia
2005